Status report
Get it in writing
The official USPTO status record for TREVARUM, serial 79180971, as a dated PDF. One price, one document, delivered in about a minute.
INSTANT DELIVERY
Trademark Status Report
$7.99
The USPTO's own status record for this mark, on one dated page.
- Current status with a plain-English verdict
- Owner, classes, filing basis, and every key date
- The mark as it appears on the federal record
- Every prosecution event, filing to today
- Source-cited with the exact retrieval date
Built from the USPTO's TSDR record. Assignment chain of title and TTAB proceeding files sit in separate USPTO systems and are not included.
Preview
◆ TRADEMARKCHECKER.AITRADEMARK STATUS REPORT
TREVARUMSerial 79180971 · Principal Register
Dead · Cancelled
Owner: Novartis AG
Class 005 - Pharmaceuticals
Filed Oct 21, 2015
Registered May 31, 2016
The record shows that TREVARUM is a cancelled Principal Register trademark owned by Novartis AG, a Swiss Aktiengesellschaft, and that the cancellation was recorded on Jan 13 2022 after the underlying International Registration was deemed dead. The registration covered Class 005 pharmaceutical preparations for preventing and treating a wide range of diseases—including nervous, immune, cardiovascular, metabolic, endocrine, respiratory, musculo‑skeletal and genitourinary disorders, as well as dermatology, oncology, hematology, transplantation, ophthalmology and gastroenterology uses. Because the listed goods are strictly pharmaceutical, a similar name used for non‑pharma products would be farther from the scope shown here, but any pharma‑related offering could encounter a meaningful concern. The history contains no oppositions, cancellations beyond the listed event, or other enforcement activity. I'd treat this as a notable concern if you plan a pharmaceutical brand with a comparable name.
Full event history, owner details, and verdict inside.
The way I'd use it, honestly, is as the thing you attach when a bank, a marketplace, or a co-founder asks "are we clear on the name". It answers in one page.